Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Atrial Fibrillation
100%
Anticoagulant Agent
100%
Antivitamin K
100%
Chronic Kidney Failure
100%
Malignant Neoplasm
75%
Heart Infarction
50%
Ischemic Heart Disease
50%
Disease
50%
Comorbidity
50%
Heart Failure
50%
Bleeding
50%
Dabigatran
50%
Brain Hemorrhage
50%
Antiplatelet
50%
Brain Ischemia
25%
Acute Heart Infarction
25%
Fracture
25%
Keyphrases
National Cohort Study
100%
Atrial Fibrillation
100%
Dose Reduction
100%
Non-vitamin K Antagonist Oral Anticoagulants
100%
Chronic Kidney Disease
30%
Percutaneous Coronary Intervention
23%
Myocardial Infarction
15%
Hypertension
15%
Ischemic Heart Disease
15%
Comorbidity
15%
Heart Failure
15%
Bleeding
15%
Dabigatran
15%
Subgroup Analysis
15%
Intracranial Hemorrhage
15%
CHA2DS2-VASc Score
15%
Antiplatelet Treatment
15%
HAS-BLED Score
15%
Chronic Obstructive
15%
Ischemic Stroke
7%
High Risk
7%
Nationwide Registry
7%
Absolute Risk
7%
Advanced Age
7%
Acute Myocardial Infarction
7%
Patients Included
7%
Cumulative Incidence
7%
Cox Regression Model
7%
High Age
7%
Bone Fracture
7%
Baseline Characteristics
7%
Patient-initiated
7%
Non-valvular Atrial Fibrillation
7%
Fracture Treatment
7%
Treatment Therapy
7%
Medicine and Dentistry
Cohort Analysis
100%
Vitamin K Antagonist
100%
Antithrombotic
100%
Atrial Fibrillation
100%
Drug Dose Reduction
100%
Chronic Kidney Disease
30%
Malignant Neoplasm
23%
Percutaneous Coronary Intervention
23%
Myocardial Infarction
15%
Disease
15%
Bleeding
15%
Dabigatran
15%
Cerebral Hemorrhage
15%
Heart Failure
15%
Ischemic Heart Disease
15%
Antiplatelet
15%
Subgroup Analysis
15%
CHA2DS2-VASc Score
15%
Acute Heart Infarction
7%
Brain Ischemia
7%
Proportional Hazards Model
7%
Cumulative Incidence
7%
Fracture
7%